ReviewCurrent cardiology reports2026
Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewMetabolic disorders represent a growing epidemiological and clinical challenge, associated with worsening prognosis of cardiovascular disease. These conditions cluster in patients with heart failure and cardiomyopathies, limiting therapeutic options. Although cardiomyopathies contribute substantially to the burden of heart failure, the impact of metabolic disorders on their progression remains underexplored. This review explores the complex cardiorenal and metabolic dimensions of cardiomyopathies, focusing on pathophysiological mechanisms, therapeutic innovations, and future organizational models. RECENT
findingsMetabolic disorders likely modulate genotype-phenotype expression, aggravate myocardial dysfunction, and accelerate disease progression through converging molecular mechanisms and pathways leading to energetic imbalance, inflammation and fibrosis. Novel therapies act on these pathways favouring microscopic and macroscopic reverse remodelling. A holistic and multidisciplinary approach is required to select appropriate therapies, improve disease progression and quality of life of these patients. Cardiomyopathies exemplify the complexity of heart failure, where genetic and metabolic dysfunctions coexist and act as both triggers and amplifiers of myocardial damage. DCM, HCM, HCM phenocopies and ARVC all present the burden of metabolic disorders and some of them benefit from novel therapies. SGLT2i, GLP1-RA, and non-steroidal MRA represent the forefront of a new therapeutic era, aiming at pleiotropic targets beyond neurohormonal blockade. Integrated care models will reshape disease management and improve patients' outcomes. Future research should investigate on metabolic disorders prevalence in cardiomyopathies and better characterize molecular pathways and phenotypic profiles that mostly benefit from novel therapies.
Indexed as
Identifiers
41636929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.